AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics Recognizes May as Mental Health Awareness Month

01 May 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

15 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

10 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

25 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

25 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

19 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

23 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting

11 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

07 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

22 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

21 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Upcoming Investor Conferences

31 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

24 Oct 2023 07:00:00 By Nasdaq GlobeNewswire